熱門資訊> 正文
IDEAYA Biosciences和Servier合作开发眼癌治疗
2025-09-02 21:54
- IDEAYA Biosciences (NASDAQ:IDYA) and Servier, an independent international pharmaceutical group, have signed a licensing agreement to develop darovasertib, a treatment for a rare eye cancer.
- According to the deal, Servier will have the rights to regulate and sell darovasertib in all regions except the United States, where IDEAYA will maintain its rights.
- As part of the agreement, IDEAYA will receive an initial payment of $210M.
- Additionally, IDEAYA could earn up to $100M based on regulatory milestones and up to $220M from commercial milestones, along with royalties on sales outside the United States.
More on IDEAYA Biosciences
- Ideaya Biosciences: Moving Into ADCs For Solid Tumors
- Seeking Alpha’s Quant Rating on IDEAYA Biosciences
- Historical earnings data for IDEAYA Biosciences
- Financial information for IDEAYA Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
